PFO
TMBR

Pathstone Family Office’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Pathstone Family Office’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2
Closed – – 1040
2020
Q2 		$0 Buy
+2
New +$349 ﹤0.01% 1024

Other funds holding TMBR

BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Pathstone Family Office's TMBR Position: Q3 2020 in Review

Pathstone Family Office sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q3 2020, closing a stake of 2 shares.

Pathstone Family Office first reported a position in TMBR in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 6 funds tracked by Wall St. Rank hold TMBR as of Q3 2020.

  • Pathstone Family Office reported no remaining Timber Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Pathstone Family Office sold 2 Timber Pharmaceuticals, Inc. shares in Q3 2020.
  • Pathstone Family Office first reported a position in Timber Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Pathstone Family Office's Timber Pharmaceuticals, Inc. position peaked at $0 in Q2 2020.
  • 6 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q3 2020.

Based on Pathstone Family Office's 13F filing for Q3 2020, filed 12 Nov 2020.